Editor of Patient Care Online.
AI-Powered Diabetes Prevention Program Intervention Matches Human Coaching in Landmark Trial
After 1 year of coaching by the AI app or a DPP-associated coach, reductions in weight and HbA1c and increases in physical activity were equal, an outcome with great promise for scalability.
Estetrol Phase 3 Trial Shows No Impact on Postmenopausal BP, Even in Women at High CV Risk
The phase 3 E4COMFORT II trial found no impact on BP after 1 year of treatment in postmenopausal women with elevated HbA1c, lipids, and TGs.
Caroline Mitchell, MD, Describes Toll of Genitourinary Syndrome of Menopause on QoL
TMS: Half of postmenopausal women suffer from GSM, yet only 25% seek treatment. Mitchell, an expert in vulvovaginal health, explains the gap and its impact on women.
FDA Green-Lights Elinzanetant, First Dual NK-1/NK-3 Antagonist, for Moderate to Severe Vasomotor Symptoms of Menopause
The novel once-daily nonhormonal therapy offers a new option to offer women who prefer not to take HRT or for whom it is contraindicated.
Marla Shapiro, CM, MDCM, on Recognizing Early Perimenopause: Sleep, Mood, and Other Missed Clues
Subtle sleep, mood, and cycle changes may herald perimenopause. Dr. Marla Shapiro discusses how clinicians can recognize and address them early.
Menopause Education Lags in Residency Training Across Primary Care Specialties
Less than one-third of residents in IM, FM, and OB/GYN programs receive structured menopause training, leaving many unprepared for midlife women’s care.
Timing of Menopausal Hormone Therapy May Impact Biomarkers of Alzheimer Disease
A secondary analysis of the ELITE trial suggests that there may be a postmenopausal "critical window" during which use of MHT is optimal.
Menopause Education Wholly Inadequate for Physician Associates, According to New Survey Results
Only 3% of physician associate respondents reported receiving more than 5 hours of menopause-related training during their professional education.
Treating Hot Flashes May Improve Cognitive Symptoms: Study Author Explains the Connection
TMS 2025: Katrina Wugalter, MA, explains why treating vasomotor symptoms may be key to improving cognitive function during menopause.
APOE ε4 and Inflammation Amplify Risk for Memory Decline in Women with Earlier Menopause
Earlier menopause, APOE ε4, and age-related inflammation combine to accelerate memory decline, revealing key factors in women’s Alzheimer disease risk.
Inequities in Menopause Care: How Provider and Patient Factors Combine to Limit Treatment
TMS: Menopause care isn’t one-size-fits-all—and that’s the problem. Wake Forest data reveal deep disparities in who gets treated and how.
Semaglutide CV Effects Appear Independent of Baseline Adiposity, Suggesting Disease-Modifying Potential
In a subanalysis of the SELECT trial, semaglutide was associated with reduction in MACE across weight and waist circumference categories, independent of body fat.
Donna Plecha, MD: Why You Should Start Breast Cancer Risk Assessment at Age 25
TMS 2025: Donna Plecha, MD, an expert in breast imaging, discusses essential breast cancer screening recommendations for primary care physicians.
Topline Real-World Data Show Fezolinetant Improves VMS, Sleep, and Work Productivity in Women With Confirmed Menopausal VMS
TMS: New preliminary data show reduction in bothersome VMS as early as week 4, an effect that led to statistically significant improvements across other life domains.
Four Studies Build Evidence for Elinzanetant as a Safe, Effective Nonhormonal Option for Menopausal Vasomotor Symptoms
TMS: New data pooled across clinical trials confirm elinzanetant’s consistent efficacy, safety, and sleep benefits across diverse populations of menopausal women.
Elinzanetant Improves Sleep Through VMS-Independent Mechanisms, According to New Pooled Analysis
TMS: Mediation analysis found that more than half of elinzanetant's sleep benefit occurs independently of nighttime hot flash reduction, challenging VMS-centric models.
Black Women Prescribed Menopausal Hormone Therapy at Significantly Lower Rates Despite More Severe Symptoms, Study Finds
TMS: Black women are up to 36% less likely to receive a prescription for systemic estrogen than White women, despite more acute and persistent VMS, authors said.
Age, Not Menopause Stage, Drives Cortical Volume Reduction in Midlife Women, New Study Suggests
TMS: Findings from a large study presented at TMS 2025 counter previous reports suggesting menopause-specific effects on brain structure at midlife.
Study Finds Atypical MI Causes More Frequent in Women Aged Under 65: Daily Dose
Your daily dose of the clinical news you may have missed.
New Large-Scale Study Challenges Previous Research on Menopause and Brain Structure
New research presented at TMS 2025 suggests menopause stage does not accelerate brain volume loss—age does. Study author discusses clinical implications for PCPs.
Early Natural Menopause Associated With Increased Metabolic Syndrome Risk, According to New Research
TMS 2025: Early natural menopause significantly raises the risk of metabolic syndrome, highlighting the need for proactive health interventions in at-risk women.
Pooled Safety Analysis Supports Elinzanetant for Vasomotor Symptoms Through 52 Weeks
Analysis of 4 clinical trials, including 3 from the phase 3 OASIS development program, found treatment-emergent AEs comparable between elinzanetant and placebo.
Plasma Biomarkers Achieve High Accuracy for Confirmatory Aβ Positivity in Eligibility Test for DMT in Alzheimer Disease
Plasma assays combining p-tau217 and Aβ42/40 accurately confirm AD, supporting patient eligibility for anti-amyloid disease-modifying therapies.
Provider Specialty and Type Drive Divergent Prescribing Patterns for Symptoms of Menopause
TMS 2025: Wide variability in practice patterns suggests a need for standardized education across both specialties and provider types to ensure consistent quality of care.
6 Latent Menopausal Phenotypes Identified by Machine Learning in 10-Year SWAN Follow-Up
TMS 2025: Machine learning uncovered 6 menopausal phenotypes, linking symptom patterns and metabolic risk and potential for personalized treatment strategies.
Orforglipron Achieves Up to 12% Weight Loss in Obesity Phase 3 Study: Daily Dose
Oral Semaglutide Wins Approval to Reduce Risk of MACE in Adults with T2D at High Risk
The first FDA-approved oral GLP-1 receptor agonist received an expanded indication for both primary and secondary prevention in T2D patients at elevated CV risk.
FDA Approves TSLP Inhibitor Tezepelumab for Chronic Rhinosinusitis With Nasal Polyps
Tezepelumab's approval marks the first for a TSLP-targeting biologic for CRSwNP, backed by WAYPOINT trial data showing sustained symptom and polyp reduction.
Grail Reports Strong Performance for Galleri Blood Test Ahead of FDA Submission
GRAIL's PATHFINDER 2 study shows Galleri blood test detected 7 times more cancers when added to standard screenings, with 99.6% specificity and low false positives.
Most Parents Support Childhood Vaccines, But Doubt Flu and COVID-19 Shots: Daily Dose
